| BID | 6.62 | ASK | 7.43 | ||
| Open | 6.85 | Previous Close | 6.75 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 13.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 84.40 | Finscreener Ranking | ★ 42.07 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★ 39.68 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★+ 55.51 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 18.49 | Earnings Rating | Strong Sell | |
| Market Cap | 260.22M | Earnings Date | 15th Nov 2023 | |
| Alpha | 0.02 | Standard Deviation | 0.19 | |
| Beta | 1.26 |
Today's Price Range 6.567.07 | 52W Range 5.7812.65 | 5 Year PE Ratio Range -141.0094.10 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 6.47% | ||
| 1 Month | -13.57% | ||
| 3 Months | -27.73% | ||
| 6 Months | -37.85% | ||
| 1 Year | -16.87% | ||
| 3 Years | 50.00% | ||
| 5 Years | 130.38% | ||
| 10 Years | 114.29% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 0.36 | |||
ROE last 12 Months | 5.83 | |||
ROA (5Y Avg) | 0.16 | |||
ROA last 12 Months | 3.99 | |||
ROC (5Y Avg) | -0.11 | |||
ROC last 12 Months | 5.20 | |||
Return on invested Capital Q | 0.02 | |||
Return on invested Capital Y | 2.35 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 1.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 106.40 | ||||
| 5.40 | ||||
| 10.61 | ||||
| 59.00 | ||||
| 234.30 | ||||
| 0.20 | ||||
| 5.99 | ||||
| 2.16 | ||||
| 357.12M | ||||
| Forward PE | -30.52 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.70 | ||||
| 4.40 | ||||
| 0.07 | ||||
| 0.09 | ||||
| 88.00 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 43.50 | ||||
| 0.60 | ||||
| 0.60 | ||||
| 2.10 | ||||
| 5.58 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 38.61M | ||||
| 1.07 | ||||
| 3.78 | ||||
| 7.49 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.03 | -0.14 | -366.67 |
| Q01 2023 | -0.02 | -0.22 | -1 000.00 |
| Q04 2022 | 0.01 | -0.14 | -1 500.00 |
| Q03 2022 | -0.05 | 0.00 | 100.00 |
| Q02 2022 | -0.03 | 0.06 | 300.00 |
| Q01 2022 | -0.01 | 0.01 | 200.00 |
| Q04 2021 | - | 0.04 | - |
| Q03 2021 | 0.00 | -0.04 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.11 | -83.33 | Negative |
| 12/2023 QR | -0.10 | -233.33 | Negative |
| 12/2023 FY | -0.56 | -64.71 | Negative |
| 12/2024 FY | -0.23 | -76.92 | Negative |
| Next Report Date | 15th Nov 2023 |
| Estimated EPS Next Report | -0.11 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 42.63K |
| Shares Outstanding | 36.91K |
| Shares Float | 36.54M |
| Trades Count | 492 |
| Dollar Volume | 294.11K |
| Avg. Volume | 81.54K |
| Avg. Weekly Volume | 68.44K |
| Avg. Monthly Volume | 111.45K |
| Avg. Quarterly Volume | 64.73K |
EDAP TMS S.A. (NASDAQ: EDAP) stock closed at 6.75 per share at the end of the most recent trading day (a -2.46% change compared to the prior day closing price) with a volume of 83.63K shares and market capitalization of 260.22M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 216 people. EDAP TMS S.A. CEO is Marc Oczachowski.
The one-year performance of EDAP TMS S.A. stock is -16.87%, while year-to-date (YTD) performance is -36.68%. EDAP stock has a five-year performance of 130.38%. Its 52-week range is between 5.78 and 12.65, which gives EDAP stock a 52-week price range ratio of 18.49%
EDAP TMS S.A. currently has a PE ratio of 106.40, a price-to-book (PB) ratio of 5.40, a price-to-sale (PS) ratio of 10.61, a price to cashflow ratio of 59.00, a PEG ratio of -, a ROA of 3.99%, a ROC of 5.20% and a ROE of 5.83%. The company’s profit margin is 5.58%, its EBITDA margin is 0.60%, and its revenue ttm is $38.61 Million , which makes it $1.07 revenue per share.
Of the last four earnings reports from EDAP TMS S.A., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. EDAP TMS S.A.’s next earnings report date is 15th Nov 2023.
The consensus rating of Wall Street analysts for EDAP TMS S.A. is Strong Buy (1), with a target price of $13, which is +84.40% compared to the current price. The earnings rating for EDAP TMS S.A. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
EDAP TMS S.A. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
EDAP TMS S.A. has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.46, ATR14 : 0.46, CCI20 : 63.69, Chaikin Money Flow : 0.02, MACD : -0.24, Money Flow Index : 46.29, ROC : -1.75, RSI : 45.31, STOCH (14,3) : 58.69, STOCH RSI : 0.68, UO : 61.89, Williams %R : -41.31), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of EDAP TMS S.A. in the last 12-months were:
EDAP TMS S.A.
Edap TMS SAis a holding company operating in two divisions namely, High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU division develops, manufactures and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets two HIFU devices: the Ablatherm, treatment of organ-confined prostate cancer; and the Focal One, for the focal therapy of localized prostate cancer destroying targeted cancer cells only. The UDS division develops, markets, manufactures and services medical devices for the invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The business of the presence of the firm are sen Asia, France, United States and other regions.
CEO: Marc Oczachowski
Telephone: +33 472153150
Address: Parc d'Activites La Poudrette-Lamartine, Vaulx-en-Velin 69120, , FR
Number of employees: 216
